CN111647076B - 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用 - Google Patents
抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用 Download PDFInfo
- Publication number
- CN111647076B CN111647076B CN202010342836.5A CN202010342836A CN111647076B CN 111647076 B CN111647076 B CN 111647076B CN 202010342836 A CN202010342836 A CN 202010342836A CN 111647076 B CN111647076 B CN 111647076B
- Authority
- CN
- China
- Prior art keywords
- cov
- heavy chain
- sars
- antibody
- domain antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010003723 Single-Domain Antibodies Proteins 0.000 title claims abstract description 41
- 230000003472 neutralizing effect Effects 0.000 title claims abstract description 24
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 abstract description 22
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 abstract description 8
- 241000700605 Viruses Species 0.000 abstract description 8
- 208000025721 COVID-19 Diseases 0.000 abstract description 7
- 241001112090 Pseudovirus Species 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000002823 phage display Methods 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 abstract 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 24
- 239000008055 phosphate buffer solution Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 229920001213 Polysorbate 20 Polymers 0.000 description 15
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 15
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 15
- 125000000539 amino acid group Chemical class 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- 235000020183 skimmed milk Nutrition 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 241001678559 COVID-19 virus Species 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 4
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 4
- PQWTZSNVWSOFFK-FXQIFTODSA-N Arg-Asp-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N PQWTZSNVWSOFFK-FXQIFTODSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 4
- MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 4
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 4
- HQOGXFLBAKJUMH-CIUDSAMLSA-N Glu-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N HQOGXFLBAKJUMH-CIUDSAMLSA-N 0.000 description 4
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 4
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 4
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 4
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 4
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 4
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 4
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 4
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 4
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 4
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 4
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 4
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 4
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 4
- GZWPQZDVTBZVEP-BZSNNMDCSA-N Tyr-Tyr-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O GZWPQZDVTBZVEP-BZSNNMDCSA-N 0.000 description 4
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 4
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 108010008355 arginyl-glutamine Proteins 0.000 description 4
- 108010077245 asparaginyl-proline Proteins 0.000 description 4
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 108010034529 leucyl-lysine Proteins 0.000 description 4
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 4
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 3
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 3
- BZKDJRSZWLPJNI-SRVKXCTJSA-N His-His-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O BZKDJRSZWLPJNI-SRVKXCTJSA-N 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 3
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 3
- 101710198474 Spike protein Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 2
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- QIJVAFLRMVBHMU-KKUMJFAQSA-N Lys-Asp-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QIJVAFLRMVBHMU-KKUMJFAQSA-N 0.000 description 2
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- UGTZYIPOBYXWRW-SRVKXCTJSA-N Ser-Phe-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O UGTZYIPOBYXWRW-SRVKXCTJSA-N 0.000 description 2
- GFDUZZACIWNMPE-KZVJFYERSA-N Thr-Ala-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O GFDUZZACIWNMPE-KZVJFYERSA-N 0.000 description 2
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ZCPBEAHAVUJKAE-UHTWSYAYSA-N (2s)-2-[[(2s)-2-[[(2r)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CN)CC1=CC=CC=C1 ZCPBEAHAVUJKAE-UHTWSYAYSA-N 0.000 description 1
- UCDOXFBTMLKASE-HERUPUMHSA-N Ala-Ser-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N UCDOXFBTMLKASE-HERUPUMHSA-N 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- JQFJNGVSGOUQDH-XIRDDKMYSA-N Arg-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCN=C(N)N)N)C(O)=O)=CNC2=C1 JQFJNGVSGOUQDH-XIRDDKMYSA-N 0.000 description 1
- GYWQGGUCMDCUJE-DLOVCJGASA-N Asp-Phe-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O GYWQGGUCMDCUJE-DLOVCJGASA-N 0.000 description 1
- NONWUQAWAANERO-BZSNNMDCSA-N Asp-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 NONWUQAWAANERO-BZSNNMDCSA-N 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- FGSGPLRPQCZBSQ-AVGNSLFASA-N Glu-Phe-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O FGSGPLRPQCZBSQ-AVGNSLFASA-N 0.000 description 1
- HZISRJBYZAODRV-XQXXSGGOSA-N Glu-Thr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O HZISRJBYZAODRV-XQXXSGGOSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- YZPVGIVFMZLQMM-YUMQZZPRSA-N Gly-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN YZPVGIVFMZLQMM-YUMQZZPRSA-N 0.000 description 1
- FSPVILZGHUJOHS-QWRGUYRKSA-N Gly-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CNC=N1 FSPVILZGHUJOHS-QWRGUYRKSA-N 0.000 description 1
- VBOBNHSVQKKTOT-YUMQZZPRSA-N Gly-Lys-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O VBOBNHSVQKKTOT-YUMQZZPRSA-N 0.000 description 1
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 1
- 102100021196 Glypican-5 Human genes 0.000 description 1
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 description 1
- JVEKQAYXFGIISZ-HOCLYGCPSA-N His-Trp-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(O)=O)C1=CN=CN1 JVEKQAYXFGIISZ-HOCLYGCPSA-N 0.000 description 1
- 101001040711 Homo sapiens Glypican-5 Proteins 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LSXGADJXBDFXQU-DLOVCJGASA-N Phe-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 LSXGADJXBDFXQU-DLOVCJGASA-N 0.000 description 1
- XDMMOISUAHXXFD-SRVKXCTJSA-N Phe-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O XDMMOISUAHXXFD-SRVKXCTJSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241001678561 Sarbecovirus Species 0.000 description 1
- IXZHZUGGKLRHJD-DCAQKATOSA-N Ser-Leu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IXZHZUGGKLRHJD-DCAQKATOSA-N 0.000 description 1
- 101800000904 Spike protein S1 Proteins 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 1
- TZXFLDNBYYGLKA-BZSNNMDCSA-N Tyr-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 TZXFLDNBYYGLKA-BZSNNMDCSA-N 0.000 description 1
- JHORGUYURUBVOM-KKUMJFAQSA-N Tyr-His-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O JHORGUYURUBVOM-KKUMJFAQSA-N 0.000 description 1
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 108010051673 leucyl-glycyl-phenylalanine Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108010084572 phenylalanyl-valine Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000013639 protein trimer Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 108010029384 tryptophyl-histidine Proteins 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Abstract
本发明涉及抗新型冠状病毒SARS‑Cov‑2的中和性单域抗体及其应用。该抗体至少具有重链CDR1、重链CDR2、重链CDR3之一。该抗体可用于制备针对COVID‑19的诊断试剂或诊断试剂盒、抗体药物或药物组合物。本发明通过噬菌体展示技术获得了抗新型冠状病毒SARS‑Cov‑2的中和性单域抗体，该抗体能够阻断SARS‑Cov‑2‑RBD与ACE2阳性细胞的结合，对SARS‑Cov‑2伪病毒具有显著的病毒中和作用，为COVID‑19的预防和治疗提供了有效的备选抗体药物。
Description
技术领域
本发明涉及一种抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用，属于生物医药技术领域。
背景技术
COVID-19由新型冠状病毒(Severe Acute Respiratory Syndrome Coronavirus2，SARS-CoV-2)感染诱发。SARS-CoV-2为正链单股RNA病毒，直径约80-120nm，是β冠状病毒属(Betacoronavirus)的成员[1]，与SARS-CoV同属于Sarbecovirus亚属，核酸同源性为79.5％[2]。目前SARS-CoV-2病毒的来源和天然宿主尚未明确，无法采取有效的措施来预防和阻止此病毒传播。
现有研究表明，与其他冠状病毒一样，SARS-Cov-2的宿主受体为血管紧张素转换酶2(ACE2)[3]，在肺部组织和小肠组织表达丰富[4]。SARS-CoV-2感染人体时，会通过病毒外壳上Spike蛋白S1亚基的受体识别结构域(receptor binding domain,RBD)与ACE2结合，诱发S2亚基结构的改变，进而促进病毒与宿主细胞膜的融合，介导病毒入侵宿主细胞[5]。
Spike蛋白以三聚体形式表达于病毒外壳上，每个单体结构由一个S1亚基和一个S2亚基组成。已经有研究发现，Spike蛋白三聚体上的S1蛋白的RBD存在“关闭”和“开放”的不同状态。当处于“开放”状态时，三聚体中的一个RBD处于伸展状态[6]，这种构象的精细改变介导了Spike蛋白与ACE2的识别与结合。
单域抗体(single domain antibody，sdAb)，即重链单域抗体VHH，仅包括抗体重链的可变区。单域抗体分子量小，蛋白表达水平较高，免疫原性弱、易于生产制备[7]等优势。更重要的是，单域抗体能识别抗原表面隐蔽的精细结构，可精确地瞄准、捕获目标靶点，特异性地与靶分子结合[8]。
目前，尚无SARS-CoV-2病毒特异性的疫苗和中和性抗体应用于临床。因此，通过快速、高效的SARS-Cov-2中和性抗体筛选，获得具有中和作用的人源单克隆抗体，是预防和治疗COVID-19的迫切需要。
发明内容
本发明的主要目的是：克服现有技术存在的问题，提供一种抗新型冠状病毒SARS-Cov-2的中和性单域抗体，具有针对新型冠状病毒SARS-Cov-2的高效抗病毒能力。同时，还提供该抗体的应用。
本发明解决其技术问题的技术方案如下：
一种抗新型冠状病毒SARS-Cov-2的中和性单域抗体，所述单域抗体由重链构成，其特征是，所述抗体至少具有以下技术特征之一：
i、所述重链包括重链CDR1，其氨基酸序列为：X1-F-X2-F-X3-X4-Y，其中，X1为D或S，X2为A、D或Y，X3为S或A，X4为S或D；
ii、所述重链包括重链CDR2，其氨基酸序列为：I-G-X5-I-X6-H-S-G-S-T-Y-Y-N-P-S-L-K-S-X7-V，其中，X5为E或S，X6为H或Y，X7为L或R；
iii、所述重链包括重链CDR3，其氨基酸序列为：VKDFGHLGQMAS、VKDLGFADH、VKDFVVGETAEFSY、或AREWHSGYDY。
优选地，所述重链CDR1的氨基酸序列为：DFAFSSY、SFDFSSY、SFDFSDY、或DFYFADY；
所述重链CDR2的氨基酸序列为：IGEIHHSGSTYYNPSLKSLV、IGEIHHSGSTYYNPSLKSRV、IGEIHHSGSTYYNPSLKSRV、或IGSIYHSGSTYYNPSLKSRV。
优选地，所述重链包括重链CDR1、重链CDR2以及重链CDR3；
当重链CDR1为DFAFSSY时，重链CDR2为IGEIHHSGSTYYNPSLKSLV，且重链CDR3为VKDFGHLGQMAS；
当重链CDR1为SFDFSSY时，重链CDR2为IGEIHHSGSTYYNPSLKSRV，且重链CDR3为VKDLGFADH；
当重链CDR1为SFDFSDY时，重链CDR2为IGEIHHSGSTYYNPSLKSRV，且重链CDR3为VKDFVVGETAEFSY；
当重链CDR1为DFYFADY时，重链CDR2为IGSIYHSGSTYYNPSLKSRV，且重链CDR3为AREWHSGYDY。
优选地，所述单域抗体的氨基酸序列如SEQ ID NO:5至SEQ ID NO:8之一所示。
优选地，所述重链具有标记，所述标记包括荧光标记、酶标记、以及放射性标记。
本发明还提供：
编码前文所述抗新型冠状病毒SARS-Cov-2的中和性单域抗体的核酸。
优选地，所述核酸的序列如SEQ ID NO:1至SEQ ID NO:4之一所示。
本发明还提供：
前文所述抗新型冠状病毒SARS-Cov-2的中和性单域抗体用于制备诊断试剂或诊断试剂盒、药物或药物组合物的用途。
前文所述核酸用于制备抗新型冠状病毒SARS-Cov-2的中和性单域抗体、药物或药物组合物的用途。
其中，所述药物或药物组合物具有针对新型冠状病毒SARS-Cov-2的中和性抗病毒作用。
本发明通过噬菌体展示技术获得了抗新型冠状病毒SARS-Cov-2的中和性单域抗体，该抗体能够阻断SARS-Cov-2-RBD与ACE2阳性细胞的结合，对SARS-Cov-2伪病毒具有显著的病毒中和作用，为COVID-19的预防和治疗提供了有效的备选抗体药物，具有潜在的临床应用前景。
附图说明
图1为本发明实施例1中ELISA检测富集噬菌体对抗原蛋白的结合情况图。
图2为本发明实施例2中噬菌体对SARS-Cov-2-RBD-hFc蛋白的特异性结合检测(ELISA)图。
图3为本发明实施例3的表达载体示意图。
图4为本发明实施例3的SDS-PAGE结果图。
图5为本发明实施例4的亲和力分析结果图。
图6为本发明实施例5的单域抗体阻断效应分析图。
图7为本发明实施例6的单域抗体抗伪病毒中和效应评估图。
具体实施方式
下面结合实施例对本发明作进一步详细描述。但是本发明不限于所给出的例子。所用方法如无特别说明均为常规方法，所用试剂和材料如无特别说明均为市售品。
实施例1、筛选靶向SARS-Cov-2-RBD的全人源单域抗体
以Tomlinson I&J噬菌体文库(Genservice Ltd.，Cambridge，UK，文库大小为1.47×108)的抗体序列为模板，通过PCR扩增该文库的抗体重链序列，构建单域抗体噬菌体文库。
采用噬菌体展示技术，以SARS-Cov-2-RBD his(Arg330-Val524)蛋白为阳性抗原，以SARS-Cov-2-RBD mut-hFC为阴性抗原进行筛选。
分别使用50μg/ml的上文所述SARS-Cov-2-RBD his抗原、SARS-Cov-2-RBD mut-hFc于4℃包被免疫板过夜；用含有5％脱脂奶粉，0.1％Tween-20的PBS溶液室温封闭免疫板1小时；将上文获得的单域抗体噬菌体文库以1012pfu与10％脱脂奶粉PBS溶液1:1混合后室温孵育2小时，加入封闭好的SARS-Cov-2-RBD mut-hFc抗原免疫板中(100μl/孔)，室温孵育1小时，进行阴性抗原预吸附；预吸附后上清转移至加入封闭好的SARS-Cov-2-RBD his抗原免疫板中(100μl/孔)，室温孵育1小时。用0.1％Tween-20的PBS溶液洗涤免疫板20次；100μl100mM Triethylamine室温洗脱30分钟；洗脱的噬菌体感染对数生长期的TG1细胞，扩增和回收后用于下一轮淘选。淘选后ELISA分析阳性噬菌体富集情况。
ELISA检测的具体过程为：以5μg/ml的上文所述SARS-Cov-2-RBD his抗原和阴性对照蛋白GPC5 his分别于4℃包被免疫板过夜；用含有3％脱脂奶粉，0.1％Tween-20的PBS溶液室温封闭免疫板1小时；将每一轮富集的噬菌体扩增并回收，以1:1比例与6％脱脂奶粉PBS室温孵育2小时，加入封闭好的免疫板中(100μl/孔)，室温孵育1小时；用0.1％Tween-20的PBS溶液洗涤免疫板5次；将HRP/Anti-M13 Monoclonal conjugate以1：4000比例与含5％脱脂奶粉，0.05％Tween-20的PBS溶液混合，加入洗涤好的免疫板中(50μl/孔)，室温孵育1小时；用0.05％Tween-20的PBS溶液洗涤免疫板5次；将TMB显色液加入免疫板中(100μl/孔)，室温显色3分钟后，加入0.5M硫酸终止显色(100μl/孔)；用酶联免疫检测仪在450nm波长下检测吸光值，并分析每轮扩增后噬菌体的亲和力。
结果如图1所示，在四轮富集后，富集的噬菌体群对SARS-Cov-2-RBD his抗原的亲和力显著升高。
在第四轮富集的噬菌体群中随机挑取单克隆，检测它们对SARS-Cov-2-RBD his抗原的结合特性，结果发现，有4条抗体序列发生了富集，分别为4A12，4D5，4A10和4C5。
经测序鉴定，4个抗体的DNA序列分别如SEQ ID NO：1至4所示，氨基酸序列分别如SEQ ID NO：2至8所示。
DNA序列：
抗体4A12，SEQ ID NO：1，
gaggtgcagctgttggagtctgggggaggcttggtacagcctggagggtccctgagactctcctgtgcagcctctgatttcgctttctcttcttatgaaatgagctgggtccgccaggctccagggaagggcctagagtggattggggaaatccatcatagtgggagcacctactacaacccgtccctcaagagtctagtcaccatctccagagacaattccaagaacacgctgtatctgcaaatgaacagcctgagagccgaggacacagccgtatattactgtgtgaaagatttcgggcacctcggtcaaatggcctcctggggccagggaaccctggtcaccgtctcctca。
抗体4D5，SEQ ID NO：2，
gaggtgcagctgttggagtctgggggaggcttggtacagcctggagggtccctgagactctcctgtgcagcctcttctttcgatttctcttcttatgaaatgagctgggtccgccaggctccagggaaggccctggagtggattggggaaatccatcatagtgggagcacctactacaacccgtccctcaagagtcgagtcaccatctccagagacaattccaagaacacgctgtatctgcaaatgaacagcctgagagccgaggacacagccatgtattactgtgtgaaggatttggggtttgcggaccactggggccagggaaccctggtcaccgtctcctca。
抗体4A10，SEQ ID NO：3，
gaggtgcagctgttggagtctgggggaggcttggtacagcctggagggtccctgagactctcctgtgcagcctcttctttcgatttctctgattatgaaatgagctgggtccgccaggctccagggaagggtctagagtggattggggaaatccatcatagtgggagcacctactacaacccgtccctcaagagtcgagtcaccatctccagagacaattccaagaacacgctgtatctgcaaatgaacagcctgagagccgaggacacagccacgtattactgtgtgaaagattttgtagtgggagaaaccgcggagttttcgtattggggccagggaaccctggtcaccgtctcctca。
抗体4C5，SEQ ID NO：4，
gaggtgcagctgttggagtctgggggaggcttggtacagcctggagggtccctgagactctcctgtgcagcctctgatttctatttcgctgattatgaaatgagctgggtccgccaggctccagggaaggggctagagtggattgggagtatctatcatagtgggagcacctactacaacccgtccctcaagagtcgagtcaccatctccagagacaattccaagaacacgctgtatctgcaaatgaacagcctgagagccgaggacacagccatgtattactgtgcaagagaatggcatagtggctatgactactggggccagggaaccctggtcaccgtctcctca。
氨基酸序列：
抗体4A12，SEQ ID NO：5，
EVQLLESGGGLVQPGGSLRLSCAASDFAFSSYEMSWVRQAPGKGLEWIGEIHHSGSTYYNPSLKSLVTISRDNSKNTLYLQMNSLRAEDTAVYYCVKDFGHLGQMASWGQGTLVTVSS。
该氨基酸序列中，氨基酸残基26-32(即DFAFSSY)为重链CDR1，氨基酸残基48-67(即IGEIHHSGSTYYNPSLKSLV)为重链CDR2，氨基酸残基96-107(即VKDFGHLGQMAS)为重链CDR3。
抗体4D5，SEQ ID NO：6，
EVQLLESGGGLVQPGGSLRLSCAASSFDFSSYEMSWVRQAPGKALEWIGEIHHSGSTYYNPSLKSRVTISRDNSKNTLYLQMNSLRAEDTAMYYCVKDLGFADHWGQGTLVTVSS。
该氨基酸序列中，氨基酸残基26-32(即SFDFSSY)为重链CDR1，氨基酸残基48-67(即IGEIHHSGSTYYNPSLKSRV)为重链CDR2，氨基酸残基96-104(即VKDLGFADH)为重链CDR3。
抗体4A10，SEQ ID NO：7，
EVQLLESGGGLVQPGGSLRLSCAASSFDFSDYEMSWVRQAPGKGLEWIGEIHHSGSTYYNPSLKSRVTISRDNSKNTLYLQMNSLRAEDTATYYCVKDFVVGETAEFSYWGQGTLVTVSS。
该氨基酸序列中，氨基酸残基26-32(即SFDFSDY)为重链CDR1，氨基酸残基48-67(即IGEIHHSGSTYYNPSLKSRV)为重链CDR2，氨基酸残基96-109(即VKDFVVGETAEFSY)为重链CDR3。
抗体4C5，SEQ ID NO：8，
EVQLLESGGGLVQPGGSLRLSCAASDFYFADYEMSWVRQAPGKGLEWIGSIYHSGSTYYNPSLKSRVTISRDNSKNTLYLQMNSLRAEDTAMYYCAREWHSGYDYWGQGTLVTVSS。
该氨基酸序列中，氨基酸残基26-32(即DFYFADY)为重链CDR1，氨基酸残基48-67(即IGSIYHSGSTYYNPSLKSRV)为重链CDR2，氨基酸残基96-105(即AREWHSGYDY)为重链CDR3。
实施例2、单域抗体的抗原特异性分析
本实施例采用ELISA检测实施例1的4A12、4D5、4A10和4C5噬菌体与SARS-Cov-2-RBD-hFc蛋白的结合情况。
具体过程为：分别使用5μg/ml的SARS-Cov-1-RBD-hFc、SARS-Cov-2-RBD-hFc、SARS-Cov-2-RBD mut-hFc于4℃包被免疫板过夜；用含有3％脱脂奶粉，0.05％Tween-20的PBS溶液室温封闭免疫板1小时；分别将4A12，4D5，4A10，4C5的噬菌体加入各封闭好的免疫板中(50μl/孔)，室温孵育1小时；用0.05％Tween-20的PBS溶液洗涤免疫板3次(340ul/孔)；将HRP/Anti-M13 Monoclonal conjugate以1：4000比例与含5％脱脂奶粉，0.05％Tween-20的PBS溶液混合，加入洗涤好的免疫板中(50μl/孔)，室温孵育1小时；用0.05％Tween-20的PBS溶液洗涤免疫板5次；将TMB显色液加入免疫板中(100μl/孔)，室温显色3分钟后，加入0.5M硫酸终止显色(100μl/孔)；用酶联免疫检测仪在450nm波长下检测吸光值，并分析每轮扩增后噬菌体的亲和力。
如图2所示，结果显示4A12、4D5、4A10、4C5抗体特异性识别SARS-Cov-2-RBD-hFc蛋白，但不识别SARS-Cov-1-RBD-hFc以及SARS-Cov-2-RBD mut-hFc蛋白。
实施例3、单域抗体的表达与纯化
构建实施例1各抗体的真核细胞表达载体pFUSE-4A12-hFC，pFUSE-4D5-hFC，pFUSE-4A10-hFC，pFUSE-4C5-hFC(Invivigen，San Diego，CA)，如图3所示。在293T细胞中转染后收集上清，并用protein A-Agarose分离柱进行纯化，SDS-PAGE检测抗体的纯度，如图4所示。
具体过程为：将抗体4A12，4D5，4A10，4C5的VH序列克隆到表达载体pFUSE-4A12-hFc，pFUSE-4D5-hFc，pFUSE-4A10-hFc，pFUSE-4C5-hFc中(Invivigen，San Diego，CA)中，制备质粒。用添加10％胎牛血清、100U/ml青霉素、0.1mg/ml链霉素的DMEM培养基在细胞培养皿中种5百万个HEK293T细胞，置于5％CO2，37℃培养箱中培养。当细胞密度到达60-80％时，利用PEI将10μg pFUSE-4A12-hFc，pFUSE-4D5-hFc，pFUSE-4A10-hFc，pFUSE-4C5-hFc质粒转染入HEK293T细胞；收集上清。
将收集的上清液在3500rpm、4℃条件下离心20分钟，并用0.45μm的微孔滤膜抽滤，进一步去除碎片；将上清液通过Protein A-Agarose(GE Healthcare，Piscataway，NJ)亲和柱分离纯化4A12-hFc，4D5-hFc，4A10-hFc，4C5-hFc重组蛋白。通过BCA法测定蛋白浓度，并将3μg 4A12-hFc，4D5-hFc，4A10-hFc，4C5-hFc重组蛋白进行聚丙烯酰胺凝胶电泳，得到4A12-hFc，4D5-hFc，4A10-hFc，4C5-hFc重组蛋白的条带。
实施例4、单域抗体亲和力分析
利用ELISA实验，测定4A12、4D5、4A10、4C5抗体与SARS-Cov-2-RBD his蛋白的亲和力。
具体过程为：使用5μg/ml的SARS-Cov-2-RBD his蛋白于4℃包被免疫板过夜；用含有3％脱脂奶粉，0.05％Tween-20的PBS溶液室温封闭免疫板1小时；将4A12-hFc，4D5-hFc，4A10-hFc，4C5-hFc蛋白用含有3％脱脂奶粉，0.05％Tween-20的PBS溶液分别稀释成20，10，5，2.5，1.25，0.625，0.3125，0.15625，0.078125，0.0390625，0.01953125，0.009765625ug/ml(倍比稀释)，加入封闭好的免疫板中(50μl/孔)，室温孵育1小时；用0.05％Tween-20的PBS溶液洗涤免疫板3次(340ul/孔)；将goat anti-human Fcγ-HRP以1：2000比例与3％脱脂奶粉，0.05％Tween-20的PBS溶液混合，加入洗涤好的免疫板中(50ul/孔)，室温孵育1小时；用0.05％Tween-20的PBS溶液洗涤免疫板3次；将TMB显色液加入免疫板中(100ul/孔)，室温显色3分钟后，加入0.5M硫酸终止显色(100ul/孔)；使用酶联免疫检测仪在450nm波长下检测吸光值并拟合亲和力曲线分析4A12-hFc，4D5-hFc，4A10-hFc，4C5-hFc重组蛋白亲和力。
如图5所示，结果显示4A12、4D5、4A10、4C5抗体与SARS-Cov-2-RBD his蛋白的亲和力分别为2.69nM、2.20nM、1.65nM、1.58nM。
实施例5、单域抗体对SARS-Cov-2-RBD与ACE2-CHO细胞结合的阻断
提前将4A12-hFc，4D5-hFc，4A10-hFc，4C5-hFc，Ctrl，M396抗体(此为SARS-Cov-1中和性抗体)与SARS-Cov-2-RBD-hFc蛋白室温预孵育1小时后，将106个ACE2-CHO细胞加入到混合体系中，冰上孵育1小时。PBS洗涤细胞，1：200加入Goat anti-human PE，冰上孵育1小时。PBS洗涤细胞，BD FACS Calibur上机检测SARS-Cov-2-RBD-hFc与ACE2-CHO细胞结合情况。
结果如图6所示，各单域抗体与SARS-Cov-2-RBD蛋白孵育后，能够显著抑制SARS-Cov-2-RBD与ACE2-CHO细胞的结合。
实施例6、病毒中和实验
在慢病毒包装系统中将VSV-G蛋白基因置换为SARS-Cov-2spike基因，与pLVX-EGFP-Luciferase报告基因共转染293T细胞(即以伪病毒转染)，收取48小时病毒上清，1：1稀释后待用。将ACE2-CHO细胞按104/孔接种于96孔板中培养过夜。预先将梯度稀释的各单域抗体与病毒上清37℃共孵育1小时后，加入到ACE2-CHO细胞培养板中。48小时后，检测Luciferase活性。
如图7所示，结果表明4A12、4D5、4A10、4C5抗体能够显著抑制伪病毒对ACE2-CHO细胞的感染，IC50分别为：0.19μg/ml，1.13μg/ml，0.66μg/ml，2.32μg/ml。注：图中的31A2是指发明人已申请发明专利的抗Galectin-3的全人源化单域抗体31A2。
本发明抗体可具有标记，如，荧光标记、酶标记、放射性标记等。
本发明的各单域抗体能特异性结合/识别SARS-Cov-2-RBD his抗原，对SARS-Cov-2-RBD his蛋白有较好的亲和力，能够有效抑制SARS-Cov-2入侵细胞，具有成为COVID-19预防和治疗药物的重要应用价值。
除上述实施例外，本发明还可以有其他实施方式。凡采用等同替换或等效变换形成的技术方案，均落在本发明要求的保护范围。
参考文献
[1].Zhu,N.,et al.,A Novel Coronavirus from Patients with Pneumonia inChina,2019.N Engl J Med,2020.382(8):727-733.
[2].Zhou,P.,et al.,A pneumonia outbreak associated with a newcoronavirus of probable bat origin.Nature,2020.579(7798):270-273.
[3].Lan,J.,et al.,Structure of the SARS-CoV-2 spike receptor-bindingdomain bound to the ACE2 receptor.Nature,2020.
[4].Zou,X.,et al.,Single-cell RNA-seq data analysis on the receptorACE2 expression reveals the potential risk of different human organsvulnerable to 2019-nCoV infection.Front Med,2020.
[5].Hoffmann,M.,et al.,SARS-CoV-2 Cell Entry Depends on ACE2 andTMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.Cell,2020.181(2):271-280 e278.
[6].Walls,A.C.,et al.,Structure,Function,and Antigenicity of theSARS-CoV-2 Spike Glycoprotein.Cell,2020.181(2):281-292.e286.
[7].Muyldermans,S.,Nanobodies:natural single-domain antibodies.AnnuRev Biochem,2013.82:775-797.
[8].Ingram,J.R.,F.I.Schmidt,and H.L.Ploegh,Exploiting Nanobodies'Singular Traits.Annu Rev Immunol,2018.36:695-715.
序列表
<110> 南京医科大学
<120> 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 354
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggagggtc cctgagactc 60
tcctgtgcag cctctgattt cgctttctct tcttatgaaa tgagctgggt ccgccaggct 120
ccagggaagg gcctagagtg gattggggaa atccatcata gtgggagcac ctactacaac 180
ccgtccctca agagtctagt caccatctcc agagacaatt ccaagaacac gctgtatctg 240
caaatgaaca gcctgagagc cgaggacaca gccgtatatt actgtgtgaa agatttcggg 300
cacctcggtc aaatggcctc ctggggccag ggaaccctgg tcaccgtctc ctca 354
<210> 2
<211> 345
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggagggtc cctgagactc 60
tcctgtgcag cctcttcttt cgatttctct tcttatgaaa tgagctgggt ccgccaggct 120
ccagggaagg ccctggagtg gattggggaa atccatcata gtgggagcac ctactacaac 180
ccgtccctca agagtcgagt caccatctcc agagacaatt ccaagaacac gctgtatctg 240
caaatgaaca gcctgagagc cgaggacaca gccatgtatt actgtgtgaa ggatttgggg 300
tttgcggacc actggggcca gggaaccctg gtcaccgtct cctca 345
<210> 3
<211> 360
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggagggtc cctgagactc 60
tcctgtgcag cctcttcttt cgatttctct gattatgaaa tgagctgggt ccgccaggct 120
ccagggaagg gtctagagtg gattggggaa atccatcata gtgggagcac ctactacaac 180
ccgtccctca agagtcgagt caccatctcc agagacaatt ccaagaacac gctgtatctg 240
caaatgaaca gcctgagagc cgaggacaca gccacgtatt actgtgtgaa agattttgta 300
gtgggagaaa ccgcggagtt ttcgtattgg ggccagggaa ccctggtcac cgtctcctca 360
<210> 4
<211> 348
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggagggtc cctgagactc 60
tcctgtgcag cctctgattt ctatttcgct gattatgaaa tgagctgggt ccgccaggct 120
ccagggaagg ggctagagtg gattgggagt atctatcata gtgggagcac ctactacaac 180
ccgtccctca agagtcgagt caccatctcc agagacaatt ccaagaacac gctgtatctg 240
caaatgaaca gcctgagagc cgaggacaca gccatgtatt actgtgcaag agaatggcat 300
agtggctatg actactgggg ccagggaacc ctggtcaccg tctcctca 348
<210> 5
<211> 118
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Ala Phe Ser Ser Tyr
20 25 30
Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile His His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Leu Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Lys Asp Phe Gly His Leu Gly Gln Met Ala Ser Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
<210> 6
<211> 115
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Ser Phe Asp Phe Ser Ser Tyr
20 25 30
Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Ile
35 40 45
Gly Glu Ile His His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys Val
85 90 95
Lys Asp Leu Gly Phe Ala Asp His Trp Gly Gln Gly Thr Leu Val Thr
100 105 110
Val Ser Ser
115
<210> 7
<211> 120
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Ser Phe Asp Phe Ser Asp Tyr
20 25 30
Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile His His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Thr Tyr Tyr Cys Val
85 90 95
Lys Asp Phe Val Val Gly Glu Thr Ala Glu Phe Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 8
<211> 116
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Tyr Phe Ala Asp Tyr
20 25 30
Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95
Arg Glu Trp His Ser Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
Claims (6)
1.一种抗新型冠状病毒SARS-Cov-2的中和性单域抗体，所述单域抗体由重链构成，其特征是，所述抗体具有以下全部技术特征：
所述重链包括重链CDR1、重链CDR2以及重链CDR3；
重链CDR1为DFAFSSY，重链CDR2为IGEIHHSGSTYYNPSLKSLV，且重链CDR3为VKDFGHLGQMAS。
2.根据权利要求1所述的中和性单域抗体，其特征是，所述单域抗体的氨基酸序列如SEQ ID NO:5所示。
3.根据权利要求1所述的中和性单域抗体，其特征是，所述重链具有标记，所述标记包括荧光标记、酶标记、以及放射性标记。
4.编码权利要求1至3任一项所述抗新型冠状病毒SARS-Cov-2的中和性单域抗体的核酸。
5.根据权利要求4所述的核酸，其特征是，所述核酸的序列如SEQ ID NO:1所示。
6.权利要求1至3任一项所述抗新型冠状病毒SARS-Cov-2的中和性单域抗体用于制备诊断试剂或诊断试剂盒、药物的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010342836.5A CN111647076B (zh) | 2020-04-27 | 2020-04-27 | 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010342836.5A CN111647076B (zh) | 2020-04-27 | 2020-04-27 | 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111647076A CN111647076A (zh) | 2020-09-11 |
| CN111647076B true CN111647076B (zh) | 2021-02-26 |
Family
ID=72345431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010342836.5A Active CN111647076B (zh) | 2020-04-27 | 2020-04-27 | 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111647076B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023009028A1 (ru) * | 2021-07-29 | 2023-02-02 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Однодоменное антитело и его модификации, специфически связывающиеся с rbd s белка вируса sars-cov-2 |
| WO2023076881A1 (en) * | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202103404PA (en) | 2020-04-02 | 2021-04-29 | Regeneron Pharma | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| US20230348572A1 (en) | 2020-05-04 | 2023-11-02 | The Rosalind Franklin Institute | Single domain antibodies binding to sars-cov-2 spike protein |
| EP4206224A1 (en) * | 2020-08-26 | 2023-07-05 | National University Corporation Kumamoto University | Human antibody or antigen-binding fragment thereof against coronavirus spike protein |
| WO2022053056A1 (en) * | 2020-09-14 | 2022-03-17 | Vazyme Biotech Co., Ltd. | Neutralizing antibodies against sars-cov-2 |
| WO2022056712A1 (en) * | 2020-09-16 | 2022-03-24 | The Third People's Hospital Of Shenzhen | Anti-sars-cov-2 antibodies and uses thereof |
| WO2022061720A1 (zh) * | 2020-09-25 | 2022-03-31 | 中国科学技术大学 | 与SARS-CoV-2 RBD结合的羊驼源纳米抗体 |
| CN112159469B (zh) * | 2020-09-30 | 2022-08-02 | 上海市公共卫生临床中心 | 冠状病毒的抗体或其抗原结合片段 |
| CN112409488B (zh) * | 2020-10-23 | 2022-07-01 | 中国科学院上海药物研究所 | 针对多种冠状病毒的单克隆抗体及应用 |
| CN112430265B (zh) * | 2020-11-23 | 2022-04-12 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗新冠病毒中和性抗体nCoV-61及其应用 |
| CN112409479B (zh) * | 2020-11-23 | 2022-04-26 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗新冠病毒中和性抗体nCoV-121及其应用 |
| WO2022179561A1 (en) * | 2021-02-24 | 2022-09-01 | The University Of Hong Kong | Neutralizing antibodies against covid-19 and methods of use thereof |
| CN113045647B (zh) * | 2021-03-22 | 2022-04-26 | 南京传奇生物科技有限公司 | 新冠病毒SARS-CoV-2的中和性抗体及其应用 |
| CN113512114B (zh) * | 2021-08-09 | 2022-08-02 | 北京大学 | 针对SARS-CoV-2突变株的抗体及其用途 |
| JP2023057069A (ja) * | 2021-10-08 | 2023-04-20 | 国立研究開発法人理化学研究所 | 蛍光ｖｈｈ抗体 |
| CN114349851B (zh) * | 2021-12-22 | 2023-08-15 | 上海纳为生物技术有限公司 | 新冠病毒中和抗体及其制备方法和应用 |
| CN115043933B (zh) * | 2022-03-31 | 2023-08-08 | 深圳市人民医院 | 靶向新冠病毒的纳米抗体及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300172C (zh) * | 2003-11-25 | 2007-02-14 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种抗SARS－CoV免疫球蛋白抗体 |
| CN102015767A (zh) * | 2008-01-17 | 2011-04-13 | 胡马斯有限公司 | 针对SARS-CoV的交叉中和人单克隆抗体及其使用方法 |
| CN109666070B (zh) * | 2017-10-13 | 2021-02-19 | 清华大学 | 单克隆抗体mers-4v2及其编码基因和应用 |
-
2020
- 2020-04-27 CN CN202010342836.5A patent/CN111647076B/zh active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023009028A1 (ru) * | 2021-07-29 | 2023-02-02 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Однодоменное антитело и его модификации, специфически связывающиеся с rbd s белка вируса sars-cov-2 |
| WO2023076881A1 (en) * | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111647076A (zh) | 2020-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111647076B (zh) | 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用 | |
| CN111592595B (zh) | 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用 | |
| CN111995675B (zh) | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 | |
| CN113444170B (zh) | 针对新冠病毒SARS-CoV-2的单克隆抗体F10 | |
| CN113264998B (zh) | 抗新冠病毒SARS-CoV-2表面S1蛋白的单链抗体及其应用 | |
| CN112062838B (zh) | 一种抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用 | |
| Sheehan et al. | Phage and yeast display | |
| CN113563463B (zh) | 一种抗新型冠状病毒SARS-CoV-2的中和纳米抗体及其应用 | |
| AU2019323389B2 (en) | Anti-BCMA single domain antibodies and application thereof | |
| Banach et al. | Paired heavy-and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses | |
| CN113150129B (zh) | 抗新冠病毒SARS-CoV-2表面S2蛋白的单链抗体及其应用 | |
| CN113045647B (zh) | 新冠病毒SARS-CoV-2的中和性抗体及其应用 | |
| Rani et al. | Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus | |
| CN114702576B (zh) | 抗新型冠状病毒s蛋白受体结合区的单域抗体及其编码基因和应用 | |
| WO2022140422A1 (en) | Llama-derived nanobodies binding the spike protein of novel coronavirus sars-cov-2 with neutralizing activity | |
| WO2023216623A1 (zh) | SARS-CoV-2α、γ、δ和ο突变株骆驼源高亲和力纳米抗体 | |
| Pavan et al. | Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants | |
| CN114478755A (zh) | 抗新型冠状病毒的全人源抗体及其组合物与应用 | |
| Liu et al. | Isolating multiple formats of human monoclonal neutralizing antibodies against SARS-CoV-2 by in vitro site-directed antibody screening | |
| EP4174083A1 (en) | Neutralizing monoclonal antibodies against sarbecoviruses | |
| Cortay et al. | Selection of single-chain antibodies that specifically interact with vesicular stomatitis virus (VSV) nucleocapsid and inhibit viral RNA synthesis | |
| CN117069831A (zh) | 广谱中和新冠病毒的纳米抗体、含其的融合蛋白及其应用 | |
| CN117069830A (zh) | 一种针对新型冠状病毒的纳米抗体及其应用 | |
| CN115925911A (zh) | 一株羊驼源纳米抗体r67及其应用 | |
| Zhao et al. | A high potent synthetic nanobody with broad-spectrum activity neutralizes SARS-Cov-2 virus and Omicron variant through a unique binding mode |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |